Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04167358




Registration number
NCT04167358
Ethics application status
Date submitted
15/11/2019
Date registered
18/11/2019
Date last updated
26/09/2024

Titles & IDs
Public title
Linerixibat Long-term Safety, and Tolerability Study
Scientific title
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis
Secondary ID [1] 0 0
2019-003158-10
Secondary ID [2] 0 0
212358
Universal Trial Number (UTN)
Trial acronym
LLSAT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Linerixibat

Experimental: Participants receiving linerixibat - Participants who previously participated in the Phase 2 studies (BAT117213 and 201000 GLIMMER [Group 1]) and Phase 3 study (212620 GLISTEN [Group 2]), will receive linerixibat.


Treatment: Drugs: Linerixibat
All participants will receive linerixibat.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with non-serious adverse events (AEs) and Serious AEs (SAEs)
Timepoint [1] 0 0
Up to 66 months
Primary outcome [2] 0 0
Number of participants with Severe AEs
Timepoint [2] 0 0
Up to 66 months
Secondary outcome [1] 0 0
Change in domain scores of the PBC-40 over time
Timepoint [1] 0 0
Baseline and up to 65 months
Secondary outcome [2] 0 0
Change in health-related quality of life (QoL) by the Euro Quality-5 dimension-3 level (EQ-5D-3L) scores over time (Group 1 only)
Timepoint [2] 0 0
Baseline and up to 65 months
Secondary outcome [3] 0 0
Change in self-rated health by EQ VAS scores over time (Group 1 only)
Timepoint [3] 0 0
Baseline and up to 65 months
Secondary outcome [4] 0 0
Change in the Beck Depression Inventory (BDI-II) scores over time
Timepoint [4] 0 0
Baseline and up to 65 months
Secondary outcome [5] 0 0
Number of participants with clinically significant changes in hematology, biochemistry (including lipid and liver parameters), and coagulation parameters
Timepoint [5] 0 0
Baseline and up to 65 months
Secondary outcome [6] 0 0
Percentage of responders at Week 24 and Week 52 of continuous treatment (Group 2 only)
Timepoint [6] 0 0
Week 24 and Week 52 of continuous treatment
Secondary outcome [7] 0 0
Percentage of participants with maintenance of efficacy at Week 52 of continuous treatment in those that were responders at Week 24 of continuous treatment (Group 2 only)
Timepoint [7] 0 0
Week 52 of continuous treatment
Secondary outcome [8] 0 0
Change from Baseline Monthly Sleep Score (MSS) (Group 2 only)
Timepoint [8] 0 0
Baseline and up to Week 52 of continuous treatment
Secondary outcome [9] 0 0
Change from Baseline in Monthly Fatigue Score (MFS)(Group 2 only)
Timepoint [9] 0 0
Baseline and up to Week 52 of continuous treatment

Eligibility
Key inclusion criteria
* Male and female participants must be 18 to 80 years of age inclusive, at the time of signing the informed consent in the participant's parent trial BAT117213, GLIMMER or GLISTEN.
* Participants with a diagnosis of PBC and a history of associated pruritus as evidenced by randomization into a prior eligible linerixibat clinical trial (BAT117213, GLIMMER or GLISTEN).
* Participants must have completed the main treatment period in a prior eligible linerixibat clinical trial (BAT117213, GLIMMER or GLISTEN).
* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: a) is a woman of non-childbearing potential (WONCBP) or b) is a woman of childbearing potential (WOCBP) and using an acceptable contraceptive method.
* Capable of giving signed informed consent.
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Screening total bilirubin >2x upper limit of normal (ULN).
* Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >6x ULN.
* Screening estimated glomerular filtration rate (eGFR) <30 milliliters per minute per 1.73 square meter (mL/min/1.73m^2) based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
* Presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy or ascites).
* Presence of actively replicating viral hepatitis B or C (Viral Hepatitis B [HBV], viral Hepatitis C [HCV]) infection), primary sclerosing cholangitis (PSC), alcoholic liver disease and/or confirmed hepatocellular carcinoma or biliary cancer.
* Current clinically significant diarrhea in the Investigator's medical opinion.
* Current symptomatic cholelithiasis or cholecystitis.
* Current diagnosis or previous diagnosis of colorectal cancer.
* Any current malignancies (including hematologic and solid malignancies).
* History of bariatric surgery with ileal bypass at any time, or any bariatric surgery performed in the past 3 years.
* Use of Obeticholic acid: within 8 weeks prior to the date of the screening visit and may not restart until after the end of the study or early study withdrawal.
* Administration of any other ileal bile acid transporter (IBAT) inhibitor in the 1 month prior to screening until after the end of the study or early study withdrawal.
* QT interval corrected (QTc) >480 millisecond (msec) at screening (12-lead ECG)
* Participants with moderate (or greater) alcohol consumption defined as more than one standard drink per day for women and two drinks per day for men.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/07/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
2/02/2027
Actual
Sample size
Target
251
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Michigan
Country [5] 0 0
United States of America
State/province [5] 0 0
Nebraska
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
North Carolina
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Texas
Country [10] 0 0
United States of America
State/province [10] 0 0
Washington
Country [11] 0 0
Argentina
State/province [11] 0 0
Buenos Aires
Country [12] 0 0
Argentina
State/province [12] 0 0
Santa Fe
Country [13] 0 0
Belgium
State/province [13] 0 0
Brussels
Country [14] 0 0
Belgium
State/province [14] 0 0
Gent
Country [15] 0 0
Brazil
State/province [15] 0 0
Bahia
Country [16] 0 0
Brazil
State/province [16] 0 0
Goiás
Country [17] 0 0
Brazil
State/province [17] 0 0
Rio Grande Do Sul
Country [18] 0 0
Brazil
State/province [18] 0 0
São Paulo
Country [19] 0 0
Bulgaria
State/province [19] 0 0
Plovdiv
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Sofia
Country [21] 0 0
Canada
State/province [21] 0 0
Ontario
Country [22] 0 0
Canada
State/province [22] 0 0
Quebec
Country [23] 0 0
China
State/province [23] 0 0
Guangdong
Country [24] 0 0
China
State/province [24] 0 0
Jiangsu
Country [25] 0 0
China
State/province [25] 0 0
Jiangxi
Country [26] 0 0
China
State/province [26] 0 0
Jilin
Country [27] 0 0
China
State/province [27] 0 0
Sichuan
Country [28] 0 0
China
State/province [28] 0 0
Beijing
Country [29] 0 0
China
State/province [29] 0 0
Shanghai
Country [30] 0 0
China
State/province [30] 0 0
Tianjin
Country [31] 0 0
China
State/province [31] 0 0
Xi'an
Country [32] 0 0
China
State/province [32] 0 0
Zhengzhou
Country [33] 0 0
Czechia
State/province [33] 0 0
Ostrava
Country [34] 0 0
Czechia
State/province [34] 0 0
Plzen
Country [35] 0 0
Czechia
State/province [35] 0 0
Praha 4
Country [36] 0 0
France
State/province [36] 0 0
Lille cedex
Country [37] 0 0
Germany
State/province [37] 0 0
Bayern
Country [38] 0 0
Germany
State/province [38] 0 0
Nordrhein-Westfalen
Country [39] 0 0
Greece
State/province [39] 0 0
Athens
Country [40] 0 0
Israel
State/province [40] 0 0
Beer Sheva
Country [41] 0 0
Israel
State/province [41] 0 0
Haifa
Country [42] 0 0
Israel
State/province [42] 0 0
Holon
Country [43] 0 0
Israel
State/province [43] 0 0
Jerusalem
Country [44] 0 0
Israel
State/province [44] 0 0
Nahariya
Country [45] 0 0
Israel
State/province [45] 0 0
Ramat Gan
Country [46] 0 0
Israel
State/province [46] 0 0
Rehovot
Country [47] 0 0
Italy
State/province [47] 0 0
Emilia-Romagna
Country [48] 0 0
Italy
State/province [48] 0 0
Lazio
Country [49] 0 0
Italy
State/province [49] 0 0
Lombardia
Country [50] 0 0
Italy
State/province [50] 0 0
Veneto
Country [51] 0 0
Japan
State/province [51] 0 0
Chiba
Country [52] 0 0
Japan
State/province [52] 0 0
Ehime
Country [53] 0 0
Japan
State/province [53] 0 0
Fukui
Country [54] 0 0
Japan
State/province [54] 0 0
Gunma
Country [55] 0 0
Japan
State/province [55] 0 0
Hiroshima
Country [56] 0 0
Japan
State/province [56] 0 0
Hokkaido
Country [57] 0 0
Japan
State/province [57] 0 0
Kagawa
Country [58] 0 0
Japan
State/province [58] 0 0
Kanagawa
Country [59] 0 0
Japan
State/province [59] 0 0
Nagano
Country [60] 0 0
Japan
State/province [60] 0 0
Nagasaki
Country [61] 0 0
Japan
State/province [61] 0 0
Nara
Country [62] 0 0
Japan
State/province [62] 0 0
Osaka
Country [63] 0 0
Japan
State/province [63] 0 0
Shizuoka
Country [64] 0 0
Japan
State/province [64] 0 0
Tokyo
Country [65] 0 0
Mexico
State/province [65] 0 0
Ciudad De Mexico
Country [66] 0 0
Mexico
State/province [66] 0 0
Nuevo León
Country [67] 0 0
Poland
State/province [67] 0 0
Czestochowa
Country [68] 0 0
Poland
State/province [68] 0 0
Katowice
Country [69] 0 0
Poland
State/province [69] 0 0
Myslowice
Country [70] 0 0
Poland
State/province [70] 0 0
Warszawa
Country [71] 0 0
Poland
State/province [71] 0 0
Wroclaw
Country [72] 0 0
Russian Federation
State/province [72] 0 0
Kemerovo
Country [73] 0 0
Russian Federation
State/province [73] 0 0
Moscow
Country [74] 0 0
Russian Federation
State/province [74] 0 0
Samara
Country [75] 0 0
Spain
State/province [75] 0 0
Valencia
Country [76] 0 0
Switzerland
State/province [76] 0 0
Lugano
Country [77] 0 0
United Kingdom
State/province [77] 0 0
Surrey
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Basingstoke
Country [79] 0 0
United Kingdom
State/province [79] 0 0
Cambridge
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Glasgow
Country [81] 0 0
United Kingdom
State/province [81] 0 0
Hull
Country [82] 0 0
United Kingdom
State/province [82] 0 0
Liverpool
Country [83] 0 0
United Kingdom
State/province [83] 0 0
London
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Newcastle Upon Tyne
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Nottingham
Country [86] 0 0
United Kingdom
State/province [86] 0 0
Plymouth
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Reading
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is an open-label, non-comparator, global, multi-center, long-term safety study for evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus in primary biliary cholangitis (PBC) who participated in a prior clinical trial with linerixibat (BAT117123 \[NCT01899703\], 201000 GLIMMER \[NCT02966834\] (group 1) or 212620 GLISTEN \[NCT00210418\]) (group 2). All participants will receive open-label linerixibat for the duration of the study. The study duration is expected to last until the study's end or until linerixibat can be lawfully made available to participants. However, the total duration of study participation will vary by participant depending upon the time of entry relative to study end in their respective country.
Trial website
https://clinicaltrials.gov/study/NCT04167358
Trial related presentations / publications
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
US GSK Clinical Trials Call Center
Address 0 0
Country 0 0
Phone 0 0
877-379-3718
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04167358